Recent clinical updates on managing osteoarthritis flare-ups highlight a structured approach to conservative care, combining short-term rest, targeted anti-inflammatory measures, and advanced regenerative interventions like platelet-rich plasma (PRP) injections. According to Dr. Patrick Le Goux, a sports physician and rheumatologist in Puteaux, temporary rest during acute pain spikes should not exceed 48 to 72 hours to prevent muscle wasting, with gradual activity resumption as pain subsides.
Immediate Relief and Conservative Management
When joint pain intensifies, managing inflammation remains the primary objective. Applying an ice pack for 15 to 20 minutes two to three times daily helps reduce localized swelling, according to the sources. For mild to moderate pain, paracetamol serves as the first-line pharmaceutical option at doses of 500 mg to 1 g taken up to every six hours, capped at a maximum daily limit of 3 g, as detailed in recent treatment protocols. When pain escalates, clinicians may prescribe nonsteroidal anti-inflammatory drugs (NSAIDs) for brief periods to mitigate gastrointestinal, cardiovascular, and renal risks. Topical anti-inflammatory gels provide targeted relief for superficial joints like fingers and knees, while ultrasound-guided corticosteroid injections offer localized relief within 24 to 72 hours that can persist for several months, with a maximum limit of three injections per joint annually.
Advanced Regenerative and Interventional Procedures
For patients with mild to moderate knee osteoarthritis seeking alternatives to traditional surgery, platelet-rich plasma (PRP) injections offer a viable option. The procedure involves centrifuging a patient’s blood to isolate anti-inflammatory platelets before reinjecting the plasma into the joint under ultrasound guidance. A systematic review and meta-analysis published in 2025 in the journal Joint Bone Spine by Maxime Auroux demonstrated that a course of one to three PRP injections reduces pain by 20% to 30% for up to six months. While PRP treatments are not currently reimbursed by social security systems, a related outpatient procedure known as genicular artery embolization is covered. Performed under local anesthesia by an interventional radiologist, genicular artery embolization uses a microcathéter to reduce blood supply to inflamed synovial tissue, allowing patients to resume normal activities within 48 hours.
Emerging Therapies in Clinical Trials
Researchers are investigating methotrexate—traditionally utilized for rheumatoid arthritis—to target immune cell activity in inflammatory hand osteoarthritis, building on Australian trial data published in The Lancet in 2023. Meanwhile, clinical trials exploring intra-articular GLP-1 receptor agonists are underway, with initial results expected by 2027, and auricular vagus nerve stimulation studies published in The Lancet Rheumatology in late 2025 demonstrated nearly 30% pain reduction in severe knee and hand osteoarthritis cohorts.
Keep reading